KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBIT Margin: 2009-2025

Historic EBIT Margin for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -6.02%.

  • Biomarin Pharmaceutical's EBIT Margin fell 2129.00% to -6.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.89%, marking a year-over-year increase of 718.00%. This contributed to the annual value of 16.97% for FY2024, which is 929.00% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EBIT Margin of -6.02% as of Q3 2025, which was down 117.93% from 33.55% recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's EBIT Margin ranged from a high of 33.55% in Q2 2025 and a low of -14.65% during Q4 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median EBIT Margin value was 13.63% (recorded in 2024), while the average stood at 14.18%.
  • Per our database at Business Quant, Biomarin Pharmaceutical's EBIT Margin surged by 2,128bps in 2022 and then slumped by 2,129bps in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EBIT Margin (Quarterly) stood at -14.65% in 2021, then soared by 1,221bps to -2.43% in 2022, then soared by 666bps to 4.22% in 2023, then spiked by 1,738bps to 21.60% in 2024, then crashed by 2,129bps to -6.02% in 2025.
  • Its EBIT Margin was -6.02% in Q3 2025, compared to 33.55% in Q2 2025 and 30.05% in Q1 2025.